{"id":261388,"date":"2026-09-22T11:35:38","date_gmt":"2026-09-22T06:05:38","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=261388"},"modified":"2026-09-22T11:35:38","modified_gmt":"2026-09-22T06:05:38","slug":"sun-pharma-vs-cipla-vs-dr-reddys-comparison","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-cipla-vs-dr-reddys-comparison\/","title":{"rendered":"Sun Pharma vs Cipla vs Dr Reddy’s: Side-by-Side Comparison of India’s Top Pharma Stocks"},"content":{"rendered":"

Sun Pharma, Cipla and Dr Reddy’s Laboratories compared on market cap, valuation, ROE, 52-week range and dividend yield. Data as of September 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Sun Pharma vs Cipla vs Dr Reddy’s Laboratories is a side-by-side comparison of three of India’s leading pharmaceutical companies. Sun Pharma carries by far the largest market cap and highest ROE of the three, Cipla sits between the two on most valuation metrics, and Dr Reddy’s Laboratories trades at the lowest PE and PB multiples. Each company’s numbers are presented here without a declared “better” pick, since the right stock depends on an investor’s own criteria.<\/p>\n<\/p><\/div>\n

Sun Pharma vs Cipla vs Dr Reddy’s Laboratories starts with the core numbers most investors compare across leading pharmaceutical companies: market capitalisation, valuation, profitability, and the 52-week trading range. Figures below are as of September 2026 and will shift with daily price moves.<\/p>\n

Tap to Access Best Research Pieces on Univest<\/strong><\/a><\/p>\n

Also read – HDFC Bank vs ICICI Bank vs Axis Bank: Side-by-Side Comparison of Three Leading Private Banks<\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n